Position in TNGX
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$8,999,754
New position
Shares Held
287,900
first reported quarter
Ownership
0.199%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#3
of 8 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Handelsbanken Fonder AB holds $686,434,691 across 88 Biotechnology names. TNGX ranks #17 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
218,292 | $108,432,185 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
631,899 | $49,458,734 | |
| 3 | ARGX |
Argenx SE
|
52,653 | $48,849,873 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
212,275 | $39,754,862 | |
| 5 | CYTK |
Cytokinetics Inc
|
405,000 | $34,501,950 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
90,407 | $33,601,569 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
52,328 | $32,628,601 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
107,255 | $32,286,972 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,999,754 | 287,900 | Shares | Sole | 2026-07-10 | |
| No filing history on record for this holder in this stock. | ||||||